Cross Timbers Royalty Trust (CRT)

CROSS TIMBERS ROYALTY TRUST DECLARES AUGUST CASH DISTRIBUTION

CROSS TIMBERS ROYALTY TRUST DECLARES JULY CASH DISTRIBUTION

REGENXBIO Presents Positive Long-Term Data for Surabgene Lomparvovec in Wet AMD and Diabetic Retinopathy at American Society of Retina Specialists Annual Meeting

CROSS TIMBERS ROYALTY TRUST DECLARES JUNE CASH DISTRIBUTION

FDA Grants Breakthrough Therapy Designation for Calderasib (MK-1084), an Investigational KRAS G12C Inhibitor, for Certain Patients with Newly Diagnosed Metastatic KRAS G12C-Mutant Non-Small Cell Lung

IMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer